Flavio Fazioli

ORCID: 0000-0002-4308-1192
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Sarcoma Diagnosis and Treatment
  • Bone Tumor Diagnosis and Treatments
  • Musculoskeletal synovial abnormalities and treatments
  • Oral and Maxillofacial Pathology
  • Bone health and treatments
  • Reconstructive Surgery and Microvascular Techniques
  • Surgical site infection prevention
  • Cell Adhesion Molecules Research
  • Vascular Tumors and Angiosarcomas
  • Protease and Inhibitor Mechanisms
  • Management of metastatic bone disease
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Reconstructive Facial Surgery Techniques
  • Pleural and Pulmonary Diseases
  • Medical Imaging and Pathology Studies
  • MicroRNA in disease regulation
  • Colorectal and Anal Carcinomas
  • S100 Proteins and Annexins
  • Nail Diseases and Treatments
  • Cancer Immunotherapy and Biomarkers
  • Orthopedic Infections and Treatments
  • Soft tissue tumors and treatment
  • Cancer Diagnosis and Treatment
  • Histiocytic Disorders and Treatments

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2014-2024

University of Molise
2023

Italian Society of Physiotherapy
2015

University of Naples Federico II
1989-2009

Federico II University Hospital
1999-2003

Institut de Biologie Moléculaire et Cellulaire
2002

Fondazione IRCCS Istituto Nazionale dei Tumori
1998

University of Milan
1997

San Raffaele University of Rome
1997

This study aimed to identify, isolate, and characterize cancer stem cells from human primary sarcomas. We performed cytometric analyses for stemness differentiation antigens, including CD29, CD34, CD44, CD90, CD117, CD133, on 21 sarcomas the day of surgery. From sarcoma biopsies, we obtained 2 chondrosarcoma-stabilized cell lines osteosarcoma stabilized lines, which sphere formation, side population profile, gene expression, in vivo vitro assays were performed. All samples expressed CD29...

10.1096/fj.10-179036 article EN The FASEB Journal 2011-03-08

Abstract Selection of cancer patients for treatment with immune checkpoint inhibitors remains a challenge due to tumour heterogeneity and variable biomarker detection. PD-L1 expression in 24 surgical chordoma specimen was determined immunohistochemically antibodies 28-8 E1L3N. The ability patient-derived organoids detect effects nivolumab explored by quantitative qualitative immunofluorescence FACS analysis. more sensitive antibody, E1L3N (ROC = 0.896, p 0.001), associated greater diameters...

10.1038/s41416-019-0616-1 article EN cc-by British Journal of Cancer 2019-10-31

We recently developed a clinical decision support tool, capable of estimating the likelihood survival at 3 and 12 months following surgery for patients with operable skeletal metastases. After making it publicly available on www.PATHFx.org , we attempted to externally validate using independent, international data. collected data from treated 13 Italian orthopaedic oncology referral centers between 2010 2013, then applied PATHFx, which generated probability three 12-months each patient....

10.1186/s12885-015-1396-5 article EN cc-by BMC Cancer 2015-05-21

Abstract BACKGROUND The most debilitating skeletal complication of stem cell transplantation (SCT) is avascular necrosis (AVN). METHODS Two hundred seven consecutive patients were evaluated prospectively for AVN. They survived disease free more than 180 days after autologous or allogeneic SCT hematologic malignancies. diagnosis AVN in suspicious cases was confirmed by magnetic resonance imaging. Possible correlations with treatments, bone mineral density (BMD), graft versus host (GVHD), and...

10.1002/cncr.11373 article EN Cancer 2003-04-30

Abstract Background The polycomb transcription factor Yin Yang 1 (YY1) overexpression can be causally implicated in experimental tumor growth and metastasization. To date, there is no clinical evidence of YY1 involvement outcome patients with osteosarcoma. Prognosis osteosarcoma still severe only few survive beyond five years. We performed a prospective immunohistochemistry analysis to correlate immunostaining metastatic development survival selected homogeneous group Methods studied 41...

10.1186/1471-2407-11-472 article EN cc-by BMC Cancer 2011-11-02

The analysis of 236 Italian patients with Paget's bone disease showed higher clinical severity and greater frequency neoplastic degeneration among who live or descend from individuals living in the Campania region (southern Italy). A prevalent involvement spine skull, sites preferentially involved giant cell tumors complicating disease, was also shown familial cases this geographical region.The southern Italy has been recently indicated as a high prevalence area for (PDB), most pagetic...

10.1359/jbmr.060822 article EN Journal of Bone and Mineral Research 2006-09-29

Primary monotypic epithelioid angiomyolipoma of bone Aims : Monotypic is a distinct and definable variant angiomyolipoma, composed monomorphous cells that show HMB45 immunoreactivity. Angiomyolipoma, including its morphological variants, belongs to the family perivascular cell tumour. Methods results The tumour was examined using immunohistochemical staining by transmission electron microscopy. Neoplastic showed cytoplasmic granular positivity for HMB45. Conclusions Extrarenal...

10.1046/j.1365-2559.2002.01356.x article EN Histopathology 2002-03-01

Levels of coenzyme Q10 (CoQ10) and its reduced oxidized forms (ubiquinol, QH2, ubiquinone, Qox) have been determined in sperm cells seminal plasma idiopathic (IDA) varicocele-associated (VARA) asthenozoospermic patients controls. The results shown significantly lower levels form, semen samples from with asthenospermia; furthermore, the content was mainly associated spermatozoa. Interestingly, IDA exhibited CoQ10 QH2 when compared to VARA ones. QH2/Qox ratio control group. present data...

10.1046/j.0303-4569.2001.00485.x article EN Andrologia 2002-04-01

Abstract The tumor microenvironment modulates cancer growth. Extracellular vesicles (EVs) have been identified as key mediators of intercellular communication, but their role in growth is largely unexplored. Here, we demonstrate that EVs from sarcoma patients promote neoangiogenesis via a purinergic X receptor 4 (P2XR4) -dependent mechanism vitro and vivo. Using proteomic approach, analyzed the protein content plasma critical activated pathways human umbilical vein endothelial cells (HUVECs)...

10.1038/s41419-021-04069-w article EN cc-by Cell Death and Disease 2021-08-17

Chondrosarcomas (CHS) are malignant cartilaginous neoplasms with diverse morphological features, characterized by resistance to chemo- and radiation therapies. In this study, we investigated the role of tumor-associated macrophages (TAM)s in tumor tissues from CHS patients immunohistochemistry. Three-dimensional organotypic co-cultures were set up order evaluate contribution primary human cells driving an M2-like phenotype monocyte-derived macrophages, capability promote growth and/or...

10.3390/cells9041062 article EN cc-by Cells 2020-04-24

Liposarcoma (LPS) is the most common soft tissue neoplasm in adults and characterized by neoplastic adipocyte proliferation. Some subtypes of LPSs show aberrations involving chromosome 12. The frequent are t(12;16) (q13;p11) present more than 90% myxoid 12q13-15 amplification well-differentiated dedifferentiated LPSs. In this region, there important oncogenes such as CHOP (DDIT3), GLI, MDM2, CDK4, SAS, HMGA2, but also HOXC locus, involved development tumor progression. study, we evaluated...

10.3892/or.2013.2760 article EN cc-by-nc Oncology Reports 2013-10-01

The receptor for the urokinase-type plasminogen activator (uPAR) is a widely recognized master regulator of cell migration and uPAR88-92 minimal sequence required to induce motility angiogenesis by interacting with formyl peptide type 1 (FPR1). In this study, we present evidence that cyclization generates new potent inhibitor migration, extracellular matrix invasion human osteosarcoma chondrosarcoma cells expressing comparable levels FPR1 on surface. vitro, cyclized [SRSRY] prevents...

10.18632/oncotarget.9976 article EN Oncotarget 2016-06-13
Coming Soon ...